SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Biopharma Industry News for March 26: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
March 26, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 25: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
March 25, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 24: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
March 24, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Eli Lilly Among Companies Pausing Some Clinical Trials Due to COVID-19 Pandemic
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
March 23, 2020
 · 
3 min read
 · 
Alex Keown
3d Illustration of Women Feeling Headache
Drug Development
Biohaven Pharma Plans to Move Vazegepant into Phase III for Acute Migraine Treatment
The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.
March 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Industry News for March 23: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
March 23, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: March 16-20
Here’s a look at some of last week’s clinical trial news.
March 20, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 20: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
March 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
NIH Reports Successful Phase II Results in Pediatric Neurofibromatosis Study
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
March 19, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 19: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
March 19, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
January 10, 2024
 · 
8 min read
Drug Development
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01
January 10, 2024
 · 
1 min read
Drug Development
Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
January 9, 2024
 · 
3 min read
Drug Development
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery
January 9, 2024
 · 
2 min read
Drug Development
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
January 9, 2024
 · 
7 min read
Drug Development
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
January 9, 2024
 · 
7 min read
Drug Development
European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I/IIa Biomarker Study in Neurodegenerative Diseases
January 9, 2024
 · 
2 min read
Drug Development
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
January 9, 2024
 · 
7 min read
Drug Development
Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery
January 9, 2024
 · 
5 min read
Drug Development
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
January 9, 2024
 · 
7 min read
Drug Development
Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
January 9, 2024
 · 
6 min read
Drug Development
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
January 8, 2024
 · 
5 min read
Drug Development
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
January 8, 2024
 · 
9 min read
Drug Development
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause
January 8, 2024
 · 
10 min read
Business
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
January 8, 2024
 · 
6 min read
Drug Development
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 8, 2024
 · 
4 min read
Drug Development
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
January 8, 2024
 · 
6 min read
Drug Development
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
January 8, 2024
 · 
6 min read
Drug Development
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
January 8, 2024
 · 
10 min read
Drug Development
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy
January 8, 2024
 · 
3 min read
Load More